The TiLink posterior locking screw and compression anchor. Credit: SurGenTec/ Business Wire.

SurGenTec has received clearance from the US Food and Drug Administration (FDA) for its posterior sacroiliac joint fusion system, TiLink-P.

Said to be the first-of-its-kind, the new minimally invasive implant is intended for the treatment of patients with chronic sacroiliac (SI) joint pain.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It combines compression across the sacroiliac joint with a posterior implantation approach, allowing doctors to stabilise the painful area and offering patients a path to healing.

Unlike current methods, which involve multiple incisions and large bulky implants, the new minimally invasive technology only needs a single small incision and integrated implant.

Furthermore, TiLink-P facilitates the delivery of a substantial quantity of bone graft in and around the implant. It will help improve fusion and surgical outcomes.

Designed to require no additional hardware support for supporting the procedure, TiLink is approved as a stand-alone device that transfixes the ilium and sacrum.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company is presently collaborating with several navigation companies to use platforms that work in line with TiLink.

The 3D-printed titanium implant features Nanotex surface technology along with a trellis system for promoting osteointegration.

SurGenTec CEO Travis Greenhalgh said: “By combining the power of compression across the SI joint with the muscle-sparing posterior approach and the ability to reinforce with bone graft, TiLink offers surgeons a new and efficient way to enhance healing in patients.

“We anticipate that this groundbreaking technology will have a profound impact on patient outcomes and improve the overall quality of care.”

Earlier, the company received approval from the FDA for its Tilink lateral sacroiliac fusion system.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact